...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infection and Drug Resistance >Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015
【24h】

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015

机译：2014-2015年期间在英国和爱尔兰收集的呼吸道病原体对头孢比普林的敏感性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Lower respiratory tract infections (LRTIs) can cause significant morbidity and mortality and are becoming increasingly difficult to treat because of the growing prevalence of resistance to conventional antimicrobial agents. This study aimed to assess the current in vitro susceptibility of respiratory tract pathogens collected from the UK and Ireland to ceftobiprole, an advanced-generation cephalosporin, as compared with other antibiotics. Methods: Pathogens isolated from patients with LRTIs were analyzed as part of the British Society for Antimicrobial Chemotherapy Antimicrobial Resistance Surveillance Programme during 2014–2015. Antibiotic susceptibility was evaluated using European Committee on Antimicrobial Susceptibility Testing breakpoints, including the ceftobiprole pharmacokinetic/pharmacodynamic non-species-specific breakpoint when species-specific breakpoints were not available. Results: One thousand one hundred and sixty-eight isolates from community-onset LRTIs and 1,264 isolates from hospital-onset LRTIs were analyzed. The ceftobiprole susceptibility rate was 99.8% (428/429) for Streptococcus pneumoniae , 100% (502/502) for Haemophilus influenzae , and 99.6% (236/237) for Moraxella catarrhalis . All Staphylococcus aureus isolates, including methicillin-susceptible S.?aureus (MSSA; N=181) and methicillin-resistant S. aureus (MRSA; N=35), were susceptible to ceftobiprole. Overall, ceftobiprole susceptibility was observed in 88.1% (215/244) of Escherichia coli isolates, 83.4% (156/187) of Klebsiella pneumoniae isolates and 86.7% (98/113) of Enterobacter spp. isolates. Conclusion: Ceftobiprole had in vitro activity against all S. aureus (both MSSA and MRSA) isolates, and almost all S. pneumoniae isolates, as well as against Gram-negative bacteria associated with community-onset or hospital-onset LRTIs. Based on this analysis, ceftobiprole is a good treatment option when broad-spectrum antibiotic coverage is needed for LRTIs.
机译：目的：下呼吸道感染（LRTIs）可能导致严重的发病率和死亡率，并且由于对常规抗菌剂的耐药性越来越高，因此变得越来越难以治疗。这项研究旨在评估与其他抗生素相比，目前从英国和爱尔兰收集的呼吸道病原体对头孢比普尔（一种较先进的头孢菌素）的体外敏感性。方法：2014年至2015年期间，作为英国抗微生物化学疗法协会抗微生物耐药性监测计划的一部分，对从LRTIs患者中分离出的病原体进行了分析。使用欧洲药物敏感性试验委员会的断点评估抗生素的敏感性，包括在没有特定物种的断点时，包括头孢比普林药代动力学/药效学非特定物种的断点。结果：分析了168例社区感染LRTI分离株和1264株医院感染LRTI分离株。肺炎链球菌的头孢比普利敏感性为99.8％（428/429），流感嗜血杆菌为100％（502/502），卡他莫拉菌为99.6％（236/237）。所有金黄色葡萄球菌分离株，包括对甲氧西林敏感的金黄色葡萄球菌（MSSA; N = 181）和对耐甲氧西林的金黄色葡萄球菌（MRSA; N = 35），均对头孢比普林敏感。总体而言，在88.1％（215/244）的大肠杆菌分离株，83.4％（156/187）的肺炎克雷伯菌分离株和86.7％（98/113）的肠杆菌属中观察到头孢比普林敏感性。隔离株。结论：头孢比浦具有对所有金黄色葡萄球菌（MSSA和MRSA）分离株，几乎所有肺炎链球菌分离株以及与社区感染或医院感染LRTI相关的革兰氏阴性细菌的体外活性。基于此分析，当LRTI需要广谱抗生素时，头孢比普利是一种很好的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号